BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 16177264)

  • 1. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
    Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
    Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
    Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
    Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach.
    Tajiri M; Ohyama C; Wada Y
    Glycobiology; 2008 Jan; 18(1):2-8. PubMed ID: 17956937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
    Fukushima K; Satoh T; Baba S; Yamashita K
    Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia.
    Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M
    Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma.
    Sarrats A; Saldova R; Comet J; O'Donoghue N; de Llorens R; Rudd PM; Peracaula R
    OMICS; 2010 Aug; 14(4):465-74. PubMed ID: 20726802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
    Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
    Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
    Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
    Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of human prostate-specific antigen in a sandwich antibody complex.
    Stura EA; Muller BH; Bossus M; Michel S; Jolivet-Reynaud C; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):530-44. PubMed ID: 22037582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
    Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis.
    Charrier JP; Tournel C; Michel S; Comby S; Jolivet-Reynaud C; Passagot J; Dalbon P; Chautard D; Jolivet M
    Electrophoresis; 2001 May; 22(9):1861-6. PubMed ID: 11425243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples.
    Tabarés G; Jung K; Reiche J; Stephan C; Lein M; Peracaula R; de Llorens R; Hoesel W
    Clin Biochem; 2007 Mar; 40(5-6):343-50. PubMed ID: 17306785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
    Janković MM; Kosanović MM
    Clin Biochem; 2005 Jan; 38(1):58-65. PubMed ID: 15607318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia.
    Dwek MV; Jenks A; Leathem AJ
    Clin Chim Acta; 2010 Dec; 411(23-24):1935-9. PubMed ID: 20708609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.
    Valenzuela HF; Pace KE; Cabrera PV; White R; Porvari K; Kaija H; Vihko P; Baum LG
    Cancer Res; 2007 Jul; 67(13):6155-62. PubMed ID: 17616672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
    Bjartell A; Johansson R; Björk T; Gadaleanu V; Lundwall A; Lilja H; Kjeldsen L; Udby L
    Prostate; 2006 May; 66(6):591-603. PubMed ID: 16388501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.